BOC Sciences provides a wide range of research chemicals and biochemicals including inhibitors, building blocks, GMP Products, impurities and metabolites, APIs for Veterinary, Natural Compounds, ADCs, Stem Cell Molecule and chiral compounds.
| Product | Description | |
|---|---|---|
| GP 1a | GP 1a is a highly selective CB2 receptor inverse agonist (pEC50 = 7.1), which displays approximately 30-fold selectivity for CB2 receptors over CB1 receptors. Synonyms: N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno[1,2-c]pyrazole-3-carboxamide; 1-(2,4-dichlorophenyl)-6-methyl-N-(1-piperidinyl)-4H-indeno[1,2-c]pyrazole-3-carboxamide. Grades: ≥99% by HPLC. CAS No. 511532-96-0. Molecular formula: C23H22Cl2N4O. Mole weight: 441.35. |  |
| GP 2a | GP 2a is a selective CB2 receptor agonist that also dispalys modest agonism at CB1 receptors with Ki values of 7.6 and 900 nM, respectively. Synonyms: N-Cyclohexyl-1-(2,4-dichlorophenyl)-1,4-dihydro-6-methylindeno[1,2-c]pyrazole-3-carboxamide. Grades: ≥99% by HPLC. CAS No. 919077-81-9. Molecular formula: C24H23Cl2N3O. Mole weight: 440.36. | |
| GP531 | GP531 is a novel riboside with similar structural and anti-ischemic properties to the adenosine-regulating agent (ARA) acadesine. Synonyms: 5-amino-1-[(2R,3R,4S,5R)-5-[(benzylamino)methyl]-3,4-dihydroxyoxolan-2-yl]imidazole-4-carboxamide; 5-amino-1-beta-D-(5'-benzylamino-5'-deoxyribofuranosyl)imidazole-4-carboxamide; GP 531; GP-531; GP531. CAS No. 142344-87-4. Molecular formula: C16H21N5O4. Mole weight: 347.37. | |
| GPP 78 | GPP 78 is a potent inhibitor of Nicotinamide phosphoribosyltransferase (Nampt) with an IC50 value of 3 nM. Synonyms: CAY10618; NMPRTase Inhibitor; N-[1,1'-biphenyl]-2-yl-4-(3-pyridinyl)-1H-1,2,3-triazole-1-octanamide. Grades: ≥95%. CAS No. 1202580-59-3. Molecular formula: C27H29N5O. Mole weight: 439.6. | |
| GPP 78 hydrochloride | GPP 78 hydrochloride is an inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), which is subsequently converted to NAD+. It was shown to induce autophagy in neuroblastoma cells. Synonyms: GPP 78 hydrochloride; GPP78 hydrochloride; GPP-78 hydrochloride; N-[1,1'-Biphenyl]-2-yl-4-(3-pyridinyl)-1H,1,2,3-triazole-1-octanamide hydrochloride. Grades: ≥98% by HPLC. Molecular formula: C27H29N5O.HCl. Mole weight: 476.01. | |
| GPR120-IN-1 | GPR120-IN-1, a cell-permeable azaspiroundecanyl acetic acid compound, is an orally available, selective agonist of GPR120 (EC50 = ~0.35 μM) that demonstrates potent selectivity over another lipid-sensing G-protein, GPR40 (FFAR1). Synonyms: 2-[3-[2-chloro-5-(trifluoromethoxy)phenyl]-3-azaspiro[5.5]undecan-9-yl]acetic acid; GPR120 Compound A; MDK77754; MDK-77754; MDK 77754; GPR120 cpdA. CAS No. 1599477-75-4. Molecular formula: C19H23ClF3NO3. Mole weight: 405.84. | |
| GPR120 modulator 1 | GPR120 modulator 1 is useful for modulating G protein-coupled receptor 120 (GPR120). Synonyms: GPR120 modulator 1; 1050506-75-6; 2-[4-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]methoxy]-2-methylphenoxy]acetic acidAcetic acid, 2-[4-[[4-(2-chlorophenyl)-2-thiazolyl]methoxy]-2-methylphenoxy]-GPR120-modulator-1. Grades: >98%. CAS No. 1050506-75-6. Molecular formula: C19H16ClNO4S. Mole weight: 389.85. | |
| GPR120 modulator 2 | GPR120 modulator 2 is useful for modulating G protein-coupled receptor 120 (GPR120). Synonyms: GPR120 modulator 2; 1050506-87-0; 3-[4-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]methoxy]-2-methylphenyl]propanoic acidBenzenepropanoic acid, 4-[[4-(2-chlorophenyl)-2-thiazolyl]methoxy]-2-methyl-3-(4-{[4-(2-CHLOROPHENYL)-1,3-THIAZOL-2-YL]METHOXY}-2-METHYLPHENYL)PROPANOIC ACID. Grades: >98%. CAS No. 1050506-87-0. Molecular formula: C20H18ClNO3S. Mole weight: 387.88. | |
| GPR40 Activator 1 | GPR40 Activator 1 is a potent GPR40 activator for treatment of type 2 diabetes. Synonyms: GPR40 Activator 1. Grades: >98%. CAS No. 1309435-60-6. Molecular formula: C31H31NO3S. Mole weight: 497.65. | |
| GPR40 Activator 2 | GPR40 Activator 2 is a potent GPR40 activator from patents WO 2012147516 A1, WO 2012046869A1 and WO 2011078371 A1. Synonyms: GPR40 Activator 2. Grades: >98%. CAS No. 1312787-30-6. Molecular formula: C28H29NO6S2. Mole weight: 539.66. | |
| GQ-16 | GQ-16 is an effective and partial agonist for peroxisome proliferator-activated receptor γ (PPARγ) (Ki = 160 nM). It does not activate PPARα, PPARβ/δ, or RXR&alpha. Synonyms: 5Z-[(5-bromo-2-methoxyphenyl)methylene]-3-[(4-methylphenyl)methyl]-2,4-thiazolidinedione. Grades: ≥98%. CAS No. 870554-67-9. Molecular formula: C19H16BrNO3S. Mole weight: 418.3. | |
| GR 103691 | GR 103691 is a potent dopamine D3 receptor antagonist. Uses: Dopamine antagonists. Synonyms: GR 103691; GR103691; GR-103691; 4'-Acetyl-N-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-[1,1'-biphenyl]-4-carboxamide. Grades: 99%. CAS No. 162408-66-4. Molecular formula: C30H35N3O3. Mole weight: 485.62. | |
| GR 113808 | GR 113808 is a potent and selective 5-HT4 receptor antagonist (pKB = 9.43 in human colonic muscle, Kd=0.15 nM for binding to cloned human 5-HT4 receptors). GR 113808 displays > 300-fold selectivity for 5-HT4 over 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C and 5-HT3 receptors. Uses: Serotonin antagonists. Synonyms: GR 113808; GR113808; GR-113808. 1-methyl-1H-indole-3-carboxylic acid, [1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl]methyl ester. Grades: ≥98% by HPLC. CAS No. 144625-51-4. Molecular formula: C19H27N3O4S. Mole weight: 393.5. | |
| GR 125487 sulfamate | GR 125487, a potent and selective 5-HT4 antagonist, is used in many biological assays to cross confirm the 5-HT4R agonist's activity. Synonyms: GR 125487 sulfamate; GR 125487; GR125487; GR-125487. 5-Fluoro-2-methoxy-[1-[2-[(methylsulfonyl)amino]ethyl]-4-piperidinyl]-1H-indole-3-methylcarboxylate sulfamate. Grades: ≥97% by HPLC. CAS No. 859502-43-5. Molecular formula: C19H26FN3O5S.H2NSO3H. Mole weight: 524.58. | |
| GR 127935 hydrochloride | GR 127935 hydrochloride is a potent and selective 5-HT1B/1D receptor antagonist (pKi = 8.5 for both guinea pig 5-HT1D and rat 5-HT1B receptors), exhibiting > 100-fold selectivity over 5HT1A, 5-HT2A, 5-HT2C receptors and other receptor types. Synonyms: [1,1'-Biphenyl]-4-carboxamide, N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-, hydrochloride (1:1); [1,1'-Biphenyl]-4-carboxamide, N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-, monohydrochloride; N-[4-Methoxy-3-(4-methyl-1-piperazinyl)phenyl]-2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-carboxamide hydrochloride; GR127935 hydrochloride; GR-127935 hydrochloride. Grades: ≥99% by HPLC. CAS No. 148642-42-6. Molecular formula: C29H31N5O3.HCl. Mole weight: 534.06. | |
| GR 135531 | GR 135531 is a high affinity agonist of MT3 melatonin receptors, with low affinity for MT1 and MT2 melatonin receptors. GR 135531 can be used to discriminate between the melatonin receptor subtypes. Synonyms: GR 135531; GR135531; GR-1355315-Methoxycarbonylamino-N-acetyltryptamine; 5-MCA-NAT; methyl N-[3-(2-acetamidoethyl)-1H-indol-5-yl]carbamate. Grades: ≥97% by HPLC. CAS No. 190277-13-5. Molecular formula: C14H17N3O3. Mole weight: 275.31. | |
| GR 159897 | GR 159897 is a potent and selective neurokinin NK2 receptor antagonist. GR 159897 competes for binding of [3H]GR100679 to hNK2-transfected CHO cells (pKi = 9.5). Study shows that GR 159897 inhibits NK2 receptor-mediated contraction of guinea pig trachea. Synonyms: GR 159897; GR159897; GR-159897; 5-Fluoro-3-[2-[4-methoxy-4-[[(R)-phenylsulphinyl]methyl]-1-piperidinyl]ethyl]-1H-indole. Grades: ≥97% by HPLC. CAS No. 158848-32-9. Molecular formula: C23H27FN2O2S. Mole weight: 414.54. | |
| GR 46611 | GR 46611 is a 5-HT1D receptor agonist that may be beneficial for the treatment of migraine. 5-HT1D acts on the central nervous system. Synonyms: GR 46611; GR46611; GR-46611; 3-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-(4-methoxybenzyl)acrylamide. CAS No. 185259-85-2. Molecular formula: C23H27N3O2. Mole weight: 377.49. | |
| GR 55562 dihydrochloride | GR 55562 dihydrochloride is a selective and competitive 5-HT1B (5-HT1Dβ) silent antagonist (pKB values of 7.3 and 6.3 for human cloned 5-HT1B and 5-HT1D receptors, respectively). Synonyms: GR 55562 dihydrochloride; GR-55562; GR55562; GR 55562. 3-[3-(Dimethylamino)propyl]-4-hydroxy-N-[4-(4-pyridinyl)phenyl]benzamide dihydrochloride. Grades: ≥98% by HPLC. CAS No. 159533-25-2. Molecular formula: C23H25N3O2.2HCl. Mole weight: 448.39. | |
| GR 79236 | GR 79236, an effective Adenosine A1 receptor agonist, could probably be used as an anti-inflammatory agent. IC50: 3.1 nM(Ki). Uses: Gr 79236 is an effective adenosine a1 receptor agonist that could probably be used as an anti-inflammatory agent. Synonyms: GR79236; GR-79236; GR 79236. N-[(1S, trans)-2-Hydroxycyclopentyl]adenosine. Grades: 95%. CAS No. 124555-18-6. Molecular formula: C15H21N5O5. Mole weight: 351.36. | |
| GR 89696 fumarate | GR 89696 fumarate is a potent and selective κ-opioid agonist (IC50 = 0.04 nM) displaying anti-nociceptive and neuroprotective activity. Synonyms: GR 89696 fumarate; GR 89696; GR89696; GR-89696. 4-[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazinecarboxylic acid methyl ester fumarate. Grades: ≥99% by HPLC. CAS No. 126766-32-3. Molecular formula: C19H25Cl2N3O3.C4H4O4. Mole weight: 530.4. | |
| GRA Ex-25 | GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively. GCGR has evolved as an attractive therapeutic target for the treatment of type II diabetes mellitus. Synonyms: 3- (4- ( (1- (4- (tert-butyl) cyclohexyl) -3- (4- (trifluoromethoxy) phenyl) ureido) methyl) benzamido) propanoic acid; GRA Ex-25; GRA Ex 25; GRA Ex25; GRAEx-25; GRAEx 25; GRAEx25. CAS No. 307983-31-9. Molecular formula: C29H36F3N3O5. Mole weight: 563.61. | |
| Granisetron hydroChloride | Granisetron HCl is a serotonin 5-HT3 receptor antagonist. Grades: >98%. CAS No. 107007-99-8. Molecular formula: C18H24N4O.HCl. Mole weight: 348.87. | |
| Grepafloxacin | Grepafloxacin is a quinoline antibacterial agent used to treat various bacterial infections. Uses: Antibacterial agent. Synonyms: Raxar; 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid. CAS No. 119914-60-2. Molecular formula: C19H22FN3O3. Mole weight: 359.401. | |
| Grepafloxacin Hydrochloride | The hydrochloride salt form of Grepafloxacin, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor and was once studied as an antibacterial agent. Synonyms: GREPAFLOXACIN HCL; OPC-17116; OPC 17116; OPC17116; 1-Cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid hydrochloride (1:1);Grepafloxacin hydrochloride; D02178; Gpfx; Grepafloxacin hydrochloride (jan/usan);Raxar;Raxar (tn). Grades: 98%. CAS No. 161967-81-3. Molecular formula: C19H22FN3O3.HCl. Mole weight: 395.86. | |
| GRL-117C | GRL-117C is a CCR5 inhibitor that can inhibit the replication of wild-type R5-HIV-1. Synonyms: (4-Nitrophenyl)Methyl N-Allyl-N-[8-[4-[Benzenesulfonyl(Methyl)Amino]-3-Methyl-3-Phenyl-Butyl]-8-Azabicyclo[3.2.1]Octan-3-Yl]Carbamate; GRL117C; GRL 117C. Molecular formula: C36H44N4O6S. Mole weight: 660.8. | |
| GS-283 | GS-283, an isoquinolin derivative, has been found to be histamine receptor and muscarinic receptor blocker. Synonyms: GS 283; GS-283; GS283; 6,7-Isoquinolinediol, 3,4-dihydro-1-((4-methoxyphenyl)methyl)-; 7-hydroxy-1-[(4-methoxyphenyl)methyl]-3,4-dihydro-2H-isoquinolin-6-one. Grades: 98%. CAS No. 149440-36-8. Molecular formula: C17H17NO3. Mole weight: 283.33. | |
| GS 39783 | GS 39783 is an allosteric positive modulator of GABAB receptors, decreases cocaine self-administration, blocks the rewarding properties of nicotine and produces anxiolytic-like activity without the side effects associated with baclofen or benzodiazepines. Uses: Positive allosteric modulator of gabab receptor function. Synonyms: GS39783; GS-39783; GS 39783; N,N'-Dicyclopentyl-2-(methylthio)-5-nitro-4,6-pyrimidinediamine;4-N,6-N-dicyclopentyl-2-methylsulfanyl-5-nitropyrimidine-4,6-diamine. Grades: ≥98%. CAS No. 39069-52-8. Molecular formula: C15H23N5O2S. Mole weight: 337.44. | |
| GS 6201 | GS 6201 is a selective A2B antagonist. Synonyms: CVT6883; CVT 6883; CVT-6883; GS6201; GS-6201; GS 6201; 3-Ethyl-3,9-dihydro-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]-1H-pyrazol-4-yl]-1H-purine-2,6-dione. CAS No. 752222-83-6. Molecular formula: C21H21F3N6O2. Mole weight: 446.43. | |
| GS-7340 fumarate | Tenofovir alafenamide fumarate, also known as Tenofovir alafenamide hemifumarate; TAF, GS-7340, is a nucleotide reverse transcriptase inhibitor and a novel prodrug of tenofovir. It is under development by Gilead Sciences for use in the treatment of HIV infection. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (Viread), Tenofovir alafenamide has greater antiviral activity and better distribution into lymphoid tissues than that agent. Gilead has announced a phase 3 clinical trial evaluating a single-tablet regimen combining GS-7340 with cobicistat, emtricitabine and elvitegravir and plans to coformulate the drug with cobicistat, emtricitabine and the protease inhibitor darunavir. In a 48 week study comparing Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate to elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide fumarate, the results showed the prodrug to be non inferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function. Synonyms: GS-7340 fumarate; GS 7340 fumarate; GS7340 fumarate; (S)-isopropyl 2- ( ( (S)- ( ( ( (R)-1- (6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl) (phenoxy)phosphoryl)amino)propanoate fumarate; TAF; GS734; GS-734; GS 7340; Tenofovir alafenamide fumarate; trade name: Genvoya. Grades: >98%. CAS No. 379270-38-9. Molecular formula: C25H33N6O9P. Mole weight: 592.54. | |
| GS 9620 | GS 9620 is a potent and oral agonist of TLR7. Uses: Antiviral agents. Synonyms: 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; GS-9620; GS9620; Vesatolimod. Grades: 99.90%. CAS No. 1228585-88-3. Molecular formula: C22H30N6O2. Mole weight: 410.51. | |
| GSI-136 | GSI-136 is an amyloid precursor protein secretase inhibitor. Uses: γ-secretase inhibitor. Synonyms: GSI-136; GSI 136; GSI136. (S)-5-chloro-N-(3-ethyl-1-hydroxypentan-2-yl)thiophene-2-sulfonamide. Grades: ≥98%. CAS No. 443989-01-3. Molecular formula: C11H18ClNO3S2. Mole weight: 311.83. | |
| GSK0660 | GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CCL17, and CXCL10, and it may block TNFα-induced retinal leukostasis. Synonyms: GSK0660; GSK-0660; GSK 0660. Grades: 96%. CAS No. 1014691-61-2. Molecular formula: C19H18N2O5S2. Mole weight: 418.48. | |
| GSK-1014802 hydrochloride | GSK-1014802 hydrochloride is the hydrochloride form of GSK-1014802, which is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. It received orphan-drug designation from the US Food and Drug Administration in July 2013. It was developed by Convergence Pharmaceuticals. It is currently in phase II studies in bipolar depression. Uses: Gsk-1014802 hydrochloride is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. it received orphan-drug designation from the us food and drug administration in july 2013. Synonyms: GSK-1014802 hydrochloride; GSK 1014802 hydrochloride; GSK1014802 hydrochloride; (2S,5R)-5-(4-((2-Fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide hydrochloride;(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochlorideCNV1014802 hydrochloride;CNV-1014802 hydrochloride;Raxatrigine hydrochloride. Grades: >98%. CAS No. 934240-31-0. Molecular formula: C18H20ClFN2O2. Mole weight: 350.82. | |
| GSK-1070916A | GSK-1070916A is an ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora kinases B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C. Aurora kinases play essential roles in mitotic checkpoint control during mitosis, and are overexpressed by a wide variety of cancer cell types. Synonyms: GSK 1070916; GSK-1070916; GSK 1070916; GSK1070916A; GSK-1070916A; GSK 1070916A; NMI-900; NMI 900; NMI900. CAS No. 942918-07-2. Molecular formula: C30H33N7O. Mole weight: 507.63. | |
| GSK126 | GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity. GSK126 decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Synonyms: GSK2816126; GSK-2816126; GSK 2816126; GSK-126; GSK 126; (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide. Grades: 98%. CAS No. 1346574-57-9. Molecular formula: C31H38N6O2. Mole weight: 526.69. | |
| GSK-1292263 | GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. Synonyms: GSK1292263; GSK 1292263l; GSK-1292263. Grades: 0.98. CAS No. 1032823-75-8. Molecular formula: C23H28N4O4S. Mole weight: 456.561. | |
| GSK1324726A (I-BET726) | Cas No. 1300031-52-0. | |
| GSK137647A | GSK137647A, a diarylsulfonamide, is an agonist of the free fatty acid receptor 4 [GPR120 (pEC50s = 6.3, 6.2, and 6.1 at human, mouse, and rat receptors, respectively)]. Uses: A selective ffa4 agonist. Synonyms: GSK137647A; GSK-137647A; GSK 137647A; GSK137647; GSK-137647; GSK 137647; 4-methoxy-N-(2,4,6-trimethylphenyl)-benzenesulfonamide. Grades: ≥98%. CAS No. 349085-82-1. Molecular formula: C16H19NO3S. Mole weight: 305.4. | |
| GSK 143 dihydrochloride | | |
| GSK1521498 | GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating in animals and humans. It is mainly used for the treatment of obesity and alcohol dependence. It was developed by GlaxoSmithKline and in clinic phase 2. Uses: Gsk-1521498 is mainly used for the treatment of obesity and alcohol dependence. Synonyms: GSK-1521498; GSK1521498; GSK 1521498; GSK-1521498B;N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine;N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-inden-2-amine. Grades: >98 %. CAS No. 1007573-18-3. Molecular formula: C24H20F2N4. Mole weight: 402.44. | |
| GSK 1562590 hydrochloride | GSK 1562590 hydrochloride is a high affinity and selective urotensin II (UT) receptor antagonist (pKi = 9.14, 9.28, 9.34, 9.64 and 9.66 at monkey, human, mouse, cat and rat recombinant receptors, respectively). It displays selectivity for UT receptors over a range of GPCRs, ion channels, enzymes and neurotransmitter transporters. GSK 1562590 has been shown to inhibit human urotensin-II (hU-II)-induced contraction of isolated rat aorta in vitro and ex vivo. Synonyms: GSK 1562590 hydrochloride; GSK1562590 hydrochloride; GSK-1562590 hydrochloride; N-[(1R)-1-[3'-(Aminocarbonyl)[1,1'-biphenyl]-4-yl]-2-(1-pyrrolidinyl)ethyl]-6,7-dichloro-2,3-dihydro-N-methyl-3-oxo-4H-1,4-benzoxazine-4-acetamide hydrochloride; 3-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-pyrrolidin-1-ylethyl]phenyl]benzamide hydrochloride. Grades: ≥98% by HPLC. CAS No. 1003878-07-6. Molecular formula: C30H30Cl2N4O4.HCl. Mole weight: 617.95. | |
| GSK163090 | GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. Synonyms: 1-(3-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)phenyl)imidazolidin-2-one; GSK163090; GSK-163090; GSK 163090. Grades: 98%. CAS No. 844903-58-8. Molecular formula: C25H29N5O. Mole weight: 415.54. | |
| GSK 1702934A | GSK 1702934A is a potent and selective TRPC3/6 activator (EC50 = 80 and 440 nM for TRPC3 and 6, respectively). However, it exhibits no activity at TRPV4, TRPA1, M1, M4, CaV1.2, hERG, NaV1.5, or CXCR5 receptors at concentrations <10 μM. Synonyms: 1,3-Dihydro-1-[1-[(5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl)carbonyl]-4-piperidinyl]-2H-benzimidazol-2-one; 3-[1-(5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-2-carbonyl)piperidin-4-yl]-1H-benzimidazol-2-one; GSK-2934A. Grades: ≥98% by HPLC. CAS No. 924377-85-5. Molecular formula: C22H25N3O2S. Mole weight: 395.52. | |
| GSK1838705A | GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematologic malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo. Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were observed at efficacious doses. GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers. GSK1838705A inhibits ALK, with an IC(50) of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses. GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. Synonyms: GSK1838705A; GSK-1838705A; GSK-1838705A. Grades: 0.98. CAS No. 1116235-97-2. Molecular formula: C27H29FN8O3. Mole weight: 532.57. | |
| GSK-1904529a | GSK-1904529A is an IGF-1R Inhibitor, is is a promising candidate for therapeutic use in IGF-IR-dependent tumors. GSK1904529A selectively inhibits IGF-IR and IR with IC50s of 27 and 25 nmol/L, respectively. GSK1904529A blocks receptor autophosphorylation and downstream signaling, leading to cell cycle arrest. It inhibits the proliferation of cell lines derived from solid and hematologic malignancies, with multiple myeloma and Ewing's sarcoma cell lines being most sensitive. Oral administration of GSK1904529A decreases the growth of human tumor xenografts in mice, consistent with a reduction of IGF-IR phosphorylation in tumors. Despite the potent inhibitory activity of GSK1904529A on IR in vitro and in vivo, minimal effects on blood glucose levels are observed in animals at doses that show significant antitumor activity. Synonyms: GSK 4529; GSK4529; GSK-4529; GSK1904529a; GSK 1904529; GSK-1904529a. CAS No. 1089283-49-7. Molecular formula: C44H47F2N9O5S. Mole weight: 851.975. | |
| GSK1997132B | PPARγ is a ligand-activated nuclear receptor and was reported to plays a role in energy metabolism, glucose homeostasis and microglia-mediated neuroinflammation. GSK1997132B is a metabolically stable, highly potent centrally penetrant PPARγ partial agonist. Synonyms: GSK 1997132B; GSK-1997132B; GSK1997132B; GSK1997132; GSK-1997132; GSK 1997132. (R)-1-((3,5-difluoropyridin-2-yl)methyl)-2-methyl-N-(1-phenylpropyl)-1H-benzo[d]imidazole-5-carboxamide. Grades: 98%. CAS No. 1168138-37-1. Molecular formula: C24H22F2N4O. Mole weight: 420.46. | |
| GSK-2033 | This active molecular is a cell permeable, potent LXR (liver-X-receptor) antagonist. pIC50 values is 7.0 for LXRα and 7.4 for LXR&beta. GSK2033 enhances T-cell proliferation and Th1/Th2/Th17 differentiation when treatment of murine CD41 T cells. Synonyms: GSK-2033; GSK2033; GSK 2033; CHEMBL1093266;GTPL8690; SCHEMBL13280409;2,4,6-trimethyl-N-[[4-(3-methylsulfonylphenyl)phenyl]methyl]-N-[[5-(trifluoromethyl)furan-2-yl]methyl]benzenesulfonamide. Grades: 98%. CAS No. 1221277-90-2. Molecular formula: C29H28F3NO5S2. Mole weight: 591.66. | |
| GSK2110183 | GSK2110183 is an orally bioavailable pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK2110183; GSK 2110183; GSK-2110183. Grades: >98%. CAS No. 1047634-63-8. Molecular formula: C18H16Cl2F2N4OS. Mole weight: 445.31. | |
| GSK2141795 hydrochloride | GSK2141795 Hcl is a potent and selective pan-Akt inhibitor with IC50s of 180/328/38 nM for Akt1/Akt2/Akt3 respectively. Synonyms: GSK-2141795 Hydrochloride; GSK 2141795 Hydrochloride; GSK2141795 Hydrochloride; GSK2141795 HCl; Uprosertib. Grades: >98%. CAS No. 1047635-80-2. Molecular formula: C18H17Cl3F2N4O2. Mole weight: 465.71. | |
| GSK215083 | GSK215083 is a PET radioligand for the 5-hydroxytrypamine-6 (5HT6) receptor. It is a quinoline based compounds that acts by antagonising the 5-HT6 receptor. It binds to receptors 5HT6 in the striatum and 5-hydroxytryptamine-2A (5HT2A) in the frontal cortex. It is used for the treatment of Alzheimer's disease and used as a PET ligand for identification of occupancy of the 5HT6 receptor coupled with 11C. Uses: Gsk215083 is used for the treatment of alzheimer's disease and used as a pet ligand for identification of occupancy of the 5ht6 receptor coupled with 11c. Synonyms: GSK-215083; GSK 215083; GSK215083; 3-(3-Fluoro-benzenesulfonyl)-8-(4-Methyl-piperazin-1-yl)-quinoline;GSK-215083;Quinoline, 3-((3-fluorophenyl)sulfonyl)-8-(4-methyl-1-piperazinyl)-. Grades: 98%. CAS No. 607742-80-3. Molecular formula: C20H20FN3O2S. Mole weight: 385.46. | |
| GSK2190915 | GSK2190915 is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor. It exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. It also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model. It increased survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF). Synonyms: AM-803; AM 803; AM803; 3Fiboflapon; GSK2190915; GSK 2190915; GSK-2190915. Grades: >98%. CAS No. 936350-00-4. Molecular formula: C38H43N3O4S. Mole weight: 637.83. | |
| GSK2190915 sodium salt | GSK2190915(AM-803; Fiboflapon) sodium salt is a potent FLAP(5-Lipoxygenase-activating protein) inhibitor with binding IC50 of 2.9 nM. Synonyms: GSK2190915 sodium salt; GSK 2190915 sodium salt; GSK-2190915 sodium salt; GSK-2190915A; GSK 2190915A; GSK2190915A; Fiboflapon sodium; AM-803 sodium; AM 803 sodium; AM803 sodium. Grades: >98%. CAS No. 1196070-26-4. Molecular formula: C38H42N3NaO4S. Mole weight: 659.81. | |
| GSK2245035 | This active molecular is a selective TLR7 (Toll-like receptor 7) agonist with preferential Type-1 IFN-stimulating properties which is under development of GlaxoSmithKline. GSK2245035 displays potent IFNα inducing potency and IFNα/TNFα selectivity. In Aug 2015, GlaxoSmithKline completed a phase II follow-up trial for Allergic asthma and Allergic rhinitis in Canada. In Jul 2016, GlaxoSmithKline planed a phase II trial for Allergic asthma in Germany (Intranasal). Uses: Allergic asthma; allergic rhinitis. Synonyms: GSK2245035; GSK 2245035; GSK-2245035; (S)-6-amino-2-(pentan-2-yloxy)-9-(5-(piperidin-1-yl)pentyl)-7,9-dihydro-8H-purin-8-one;1325212-97-2 (maleate salt). Grades: 98%. CAS No. 1207629-49-9. Molecular formula: C20H34N6O2. Mole weight: 390.52. | |
| GSK 2250665A | GSK 2250665A is an Itk inhibitor (pKi = 9.2) displaying selectivity for Itk over Aurora B kinase and Btk (pIC50 = 6.4 and 6.5, respectively) and a panel of other kinases. GSK 2250665A was shown to inhibit IFNγ production in PBMCs. Synonyms: GSK-2250665A; GSK 2250665A; GSK2250665A; GSK-2250665; GSK 2250665; GSK2250665; trans-4-[[4-[(6-Ethyl-2-benzothiazolyl)amino]-6-(phenylmethyl)-2-pyrimidinyl]amino]cyclohexanol. Grades: ≥97% by HPLC. CAS No. 1246030-96-5. Molecular formula: C26H29N5OS. Mole weight: 459.61. | |
| GSK2269557 | GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asthma. Uses: Gsk2269557 is an effective pi3k inhibitor that could be used as against inflammatory and some autoimmune diseases. Synonyms: CHEMBL2216859; GSK2269557 (free base); GSK2269557; GSK-2269557; GSK 2269557; Nemiralisib; 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole; 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole. Grades: 95%. CAS No. 1254036-71-9. Molecular formula: C26H28N6O. Mole weight: 440.54. | |
| GSK-2269557 HCl salt | GSK-2269557 is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by GlaxoSmithKline. GSK-2269557 is highly selective for PI3Kδ over the closely related isoforms and is active in a animal model of Th2-driven lung inflammation. Treatment for Asthma and Chronic obstructive pulmonary disease(COPD) is in clinical trials Phase II. Uses: Asthma; chronic obstructive pulmonary disease. Synonyms: GSK-2269557 HCl salt; GSK 2269557 HCl salt; GSK2269557 HCl salt; 6-(1H-indol-4-yl)?-4-[5-[[4-(1-methylethyl)?-1-piperazinyl]?methyl]?-2-oxazolyl]?-1H-indazole, monohydrochloride;1254036-71-9(free base). Grades: 98%. CAS No. 1254036-77-5. Molecular formula: C26H28N6O HCl. Mole weight: 477.01. | |
| GSK2292767 | GSK2292767 is a Phosphatidylinositol 3 kinase delta inhibitor applicated for the treatment of respiratory diseases including asthma and COPD in clinical trials. GSK2292767 is highly selective for PI3Kδ over the closely related isoforms and is really active in the animal model of Th2-driven lung inflammation. Uses: Asthma and copd. Synonyms: GSK2292767; GSK-2292767; GSK 2292767. N-[5-[4-[5-[[(2R, 6S)-2, 6-dimethylmorpholin-4-yl]methyl]-1, 3-oxazol-2-yl]-1H-indazol-6-yl]-2-methoxypyridin-3-yl]methanesulfonamide; SCHEMBL173490; ZINC95938263; KB-78330; 1254036-66-2; Methanesulfonamide, N-[5-[4-[5-[[(2R, 6S)-2, 6-dimethyl-4-morpholinyl]methyl]-2-oxazolyl]-1H-indazol-6-yl]-2-methoxy-3-pyridinyl]. Grades: 98%. CAS No. 1254036-66-2. Molecular formula: C24H28N6O5S. Mole weight: 512.58. | |
| GSK-239512 | GSK-239512 is a histamine H3 receptor antagonist. In Jun 2015, Phase-II for Schizophrenia in USA was discontinued. Phase II clinical trilas for the treatment of Multiple sclerosis are on-going. Uses: Multiple sclerosis. Synonyms: GSK-239512; GSK239512; GSK 239512; 1-(6-((3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy)-3-pyridinyl)-2-Pyrrolidinone. Grades: 98%. CAS No. 720691-69-0. Molecular formula: C23H27N3O2. Mole weight: 377.48. | |
| GSK2578215A | GSK2578215A induces a dose-dependent inhibition of Ser910 and Ser935 phosphorylation in both wild-type LRRK2 and LRRK2[G2019S] stably transfected into HEK293 cells. Synonyms: GSK2578215A; GSK-2578215A; GSK 2578215A. Grades: >98%. CAS No. 1285515-21-0. Molecular formula: C24H18FN3O2. Mole weight: 399.42. | |
| GSK2578999A | GSK2578999A is a potent HIV-1 maturation inhibitor with IC50 values of 17 nM, 23 nM, 25 nM, and 8 nM for wild type, Q369H, V370A, and T371A respectively. Synonyms: GSK-8999; (3β)-3-(3-carboxy-3-methyl-1-oxobutoxy)-N-[1-(4-chlorophenyl)cyclopropyl]-α,21-dioxo-28-norlup-18-ene-17-acetamide. CAS No. 1422355-59-6. Molecular formula: C46H62ClNO7. Mole weight: 776.4. | |
| GSK2636771 | GSK2636771 is an orally bioavailable, substituted benzimidazole inhibitor of the class I phosphoinositide 3-kinase (PI3K) beta isoform with potential antineoplastic activity. PI3K beta inhibitor GSK2636771 selectively inhibits PI3K beta kinase activity in the PI3K/Akt/mTOR pathway, which may result in tumor cell apoptosis and growth inhibition in PI3K beta-expressing and/or PTEN-driven tumor cells. Dysregulation of the PI3K/Akt/mTOR pathway is frequently found in solid tumors and results in the promotion of tumor cell growth, survival, and resistance to both chemotherapy and radiotherapy. PI3K beta is the p110-beta catalytic subunit of the class I PI3K. PTEN, a tumor suppressor protein and negative regulator of PI3K activity, is often mutated in a variety of cancer cells. Uses: Antineoplastic agents. Synonyms: GSK2636771; GSK-2636771; GSK 2636771. CAS No. 1372540-25-4. Molecular formula: C22H22F3N3O3. Mole weight: 433.431. | |
| GSK2656157 | GSK2656157 is an ATP-competitive inhibitor of PERK enzyme activity with an IC50 of 0.9 nM. It is highly selective for PERK with IC50 values >100 nM against a panel of 300 kinases. GSK2656157 inhibits PERK activity in cells with an IC50 in the range of 10-30 nM as shown by inhibition of stress-induced PERK autophosphorylation, eIF2α substrate phosphorylation, together with corresponding decreases in ATF4 and CHOP proteins in multiple cell lines. Oral administration of GSK2656157 to mice shows a dose- and time-dependent pharmacodynamic response in pancreas as measured by PERK auto-phosphorylation. Twice daily dosing of GSK2656157 results in dose dependent inhibition of multiple human tumor xenografts growth in mice. Altered amino acid metabolism, decreased blood vessel density and vascular perfusion are potential mechanisms for the observed anti-tumor effect. However, despite its anti-tumor activity, given the on-target pharmacological effects of PERK inhibition on pancreatic function, development of any PERK inhibitor in human subjects would need to be cautiously pursued in cancer patients. Synonyms: GSK2656157; GSK 2656157; GSK-2656157. Grades: 0.98. CAS No. 1337532-29-2. Molecular formula: C23H21FN6O. Mole weight: 416.46. | |
| GSK269962A HCl | GSK269962 is a selective inhibitor of ROCK (Rho-associated protein kinase) with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively. GSK269962 displays > 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Synonyms: GSK269962B; GSK269962; GSK 269962. Molecular formula: C29H30N8O5·HCl. Mole weight: 607.06. | |
| GSK2801 | GSK2801 is a A Selective Chemical Probe for BAZ2B/A bromodomains. BAZ2A/B belong to a family of ubiquitously expressed bromodomain containing proteins.probes/GSK2801). Synonyms: GSK2801; GSK-2801; GSK 2801. Grades: 98%. CAS No. 1619994-68-1. Molecular formula: C20H21NO4S. Mole weight: 371.45. | |
| GSK-2818713 | GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex inhibitor, GSK-2818713 exhibited picomolar potency on genotype 1 variants. Uses: The treatment of hepatitis c. Synonyms: GSK-2818713; GSK2818713; GSK 2818713. | |
| GSK2830371 | GSK2830371 is an orally active, allosteric Wip1 phosphatase inhibitor with IC50 of 6 nM. Synonyms: GSK 2830371; GSK2830371; GSK-2830371. Grades: >98%. CAS No. 1404456-53-6. Molecular formula: C23H29ClN4O2S. Mole weight: 461.02. | |
| GSK2838232 | GSK2838232, a derivative of Betulin, is a novel human immune virus (HIV) maturation inhibitor being developed for the treatment of chronic HIV infection. Uses: Anti-hiv agents. Synonyms: GSK2838232; GSK-2838232; GSK 2838232; 4-[[(3aR, 5aR, 5bR, 7aR, 9S, 11aR, 11bR, 13aS)-3a-[(1R)-2-[(4-chlorophenyl)methyl-[2-(dimethylamino)ethyl]amino]-1-hydroxyethyl]-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo-1-propan-2-yl-4, 5, 6, 7, 7a, 9, 10, 11, 11b, 12, 13, 13a-dodecahydro-3H-cyclopenta[a]chrysen-9-yl]oxy]-2, 2-dime. Grades: 99.34%. CAS No. 1443460-91-0. Molecular formula: C48H73ClN2O6. Mole weight: 809.56. | |
| GSK2879552 | GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just planed a Phase I/II trail by GSK against Myelodysplastic syndromes. Uses: Gsk2879552 has been found to be a lsd1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. Synonyms: GSK2879552; UNII-GT77Z6Y09Z; GSK-2879552; GSK 2879552; GT77Z6Y09Z; 1401966-69-5; 4- ( (4- ( ( ( (1R, 2S) -2-Phenylcyclopropyl) amino) methyl) piperidin-1-yl) methyl) benzoic acid. Grades: 98%. CAS No. 1401966-69-5. Molecular formula: C23H28N2O2. Mole weight: 364.48. | |
| GSK3117391 | GSK3117391, a HDAC inhibitor, was developed by GSK considering its potential effect in the treatment of arthritis and rheumatoid. It was already being terminated the phase 1 trial. Uses: Gsk3117391, a hdac inhibitor, was developed by gsk considering its potential effect in the treatment of arthritis and rheumatoid. Synonyms: GSK3117391; GSK-3117391; GSK 3117391; GSK3117391A; GSK-3117391A; GSK 3117391A; HDAC-IN-3; SCHEMBL15144242; AFDPFLDWOXXHQM-NRFANRHFSA-N; CS-5448; HY-19772; 121555-EP2295410A1. Grades: 95%. CAS No. 1018673-42-1. Molecular formula: C22H33N3O4. Mole weight: 403.52. | |
Our database is helping our users find suppliers everyday.
